Shares of Precision BioSciences Inc (NASDAQ:DTIL) have been assigned an average recommendation of “Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $22.80.

A number of analysts recently issued reports on the company. HC Wainwright assumed coverage on Precision BioSciences in a report on Tuesday, July 16th. They set a “buy” rating and a $21.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on Precision BioSciences in a report on Monday, April 22nd. They set an “overweight” rating and a $23.00 price objective on the stock. Goldman Sachs Group assumed coverage on Precision BioSciences in a report on Monday, April 22nd. They set a “buy” rating and a $24.00 price objective on the stock. BTIG Research assumed coverage on Precision BioSciences in a report on Friday, August 9th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, Jefferies Financial Group assumed coverage on Precision BioSciences in a report on Monday, April 22nd. They set a “buy” rating on the stock.

Several large investors have recently added to or reduced their stakes in the business. FMR LLC purchased a new stake in shares of Precision BioSciences in the 1st quarter valued at about $67,102,000. Cowen Inc. raised its holdings in shares of Precision BioSciences by 7.5% in the 2nd quarter. Cowen Inc. now owns 1,083,926 shares of the company’s stock valued at $14,362,000 after acquiring an additional 75,361 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Precision BioSciences by 66.7% in the 2nd quarter. Wells Fargo & Company MN now owns 883,037 shares of the company’s stock valued at $11,701,000 after acquiring an additional 353,208 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Precision BioSciences by 511.8% in the 2nd quarter. BlackRock Inc. now owns 635,076 shares of the company’s stock valued at $8,414,000 after acquiring an additional 531,269 shares in the last quarter. Finally, Laurion Capital Management LP purchased a new stake in shares of Precision BioSciences in the 1st quarter valued at about $9,295,000. 39.66% of the stock is currently owned by hedge funds and other institutional investors.

DTIL traded down $0.24 during trading on Friday, reaching $9.03. 67,385 shares of the company were exchanged, compared to its average volume of 180,169. The company has a 50-day simple moving average of $12.81. Precision BioSciences has a 12-month low of $8.70 and a 12-month high of $19.00.

About Precision BioSciences

Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.

Featured Story: How Investors Can Profit from Options Trading

Analyst Recommendations for Precision BioSciences (NASDAQ:DTIL)

Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.